Henry Ford Health

Henry Ford Health Scholarly Commons
Hypertension and Vascular Research Articles

Hypertension and Vascular Research

8-1-2022

Aldehyde dehydrogenase 2 augments adiponectin signaling in
coronary angiogenesis in HFpEF associated with diabetes
Bipradas Roy
Guodong Pan
Shailendra Giri
Rajarajan A. Thandavarayan
Suresh S. Palaniyandi

Follow this and additional works at: https://scholarlycommons.henryford.com/hypertension_articles

Received: 30 March 2022

|

Revised: 13 June 2022

DOI: 10.1096/fj.202200498R

|

Accepted: 23 June 2022

RESEARCH ARTICLE

Aldehyde dehydrogenase 2 augments adiponectin signaling
in coronary angiogenesis in HFpEF associated with diabetes
Bipradas Roy1,2
| Guodong Pan1,2 | Shailendra Giri3 |
Rajarajan A. Thandavarayan4 | Suresh Selvaraj Palaniyandi1,2
1

Division of Hypertension and Vascular
Research, Department of Internal
Medicine, Henry Ford Health System,
Detroit, Michigan, USA

2

Department of Physiology, Wayne
State University, Detroit, Michigan,
USA

3

Department of Neurology, Henry Ford
Health System, Detroit, Michigan, USA

4

Department of Cardiovascular
Sciences, Houston Methodist Research
Institute, Houston, Texas, USA
Correspondence
Suresh Selvaraj Palaniyandi, Division of
Hypertension and Vascular Research,
Department of Internal Medicine,
Henry Ford Health System, Integrative
Biosciences Center (IBio), Room #3402,
6135 Woodward, Detroit, MI 48202,
USA.
Email: spalani2@hfhs.org
Funding information
American Heart Association (AHA),
Grant/Award Number: 835262; Henry
Ford Health System, Grant/Award
Number: A10249; HHS | NIH | National
Heart, Lung, and Blood Institute
(NHLBI), Grant/Award Number:
1R01HL139877-01A1

Abstract
4-hydroxy-2-nonenal (4HNE), an oxidative stress byproduct, is elevated in diabetes which decreases coronary angiogenesis, and this was rescued by the 4HNE
detoxifying enzyme, aldehyde dehydrogenase 2 (ALDH2). Adiponectin (APN),
an adipocytokine, has pro-angiogenic properties and its loss of function is critical in diabetes and its complications. Coronary endothelial cell (CEC) damage is
the initiating step of diabetes-mediated heart failure with preserved ejection fraction (HFpEF) pathogenesis. Thus, we hypothesize that ALDH2 restores 4HNE-
induced downregulation of APN signaling in CECs and subsequent coronary
angiogenesis in diabetic HFpEF. Treatment with disulfiram, an ALDH2 inhibitor, exacerbated 4HNE-mediated decreases in APN-induced increased coronary
angiogenesis and APN-signaling cascades, whereas pretreatment with alda1, an
ALDH2 activator, rescued the effect of 4HNE. We employed control mice (db/m),
spontaneous type-2 diabetic mice (db/db), ALDH2*2 knock-in mutant mice with
intrinsic low ALDH2 activity (AL), and diabetic mice with intrinsic low ALDH2
activity (AF) mice that were created by crossing db/db and AL mice to test our
hypothesis in vivo. AF mice exhibited heart failure with preserved ejection fraction (HFpEF)/severe diastolic dysfunction at 6 months with a preserved systolic
function compared with db/db mice as well as 3 months of their age. Decreased
APN-mediated coronary angiogenesis, along with increased circulatory APN levels and decreased cardiac APN signaling (index of APN resistance) were higher in
AF mice relative to db/db mice. Alda1 treatment improved APN-mediated angiogenesis in AF and db/db mice. In summary, 4HNE-induces APN resistance and a

Abbreviations: 2 h PPBS, 2-hour postprandial blood sugar; 4HNE, 4-hydroxy-2-nonenal; AdipoR1, adiponectin receptor 1; AdipoR2, adiponectin
receptor 2; AKT, protein kinase B; ALDH2, Aldehyde dehydrogenase 2; AMPK, AMP-activated protein kinase; ANOVA, analysis of variance; APN,
adiponectin; APPL1, adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1; BSA, bovine serum albumin; BW, body
weight; CC, compound C; CEC, coronary endothelial cell; CO, cardiac output; DMEM, Dulbecco's modified eagle medium; DSF, disulfiram; EDTA,
ethylenediaminetetraacetic acid; EF, ejection fraction; eNOS, endothelial nitric oxide synthase; FBS, fasting blood sugar; FS, fractional shortening;
HFpEF, heart failure with preserved ejection fraction; HMEC-1, human microvascular endothelial cell 1; HPF, high power field; HR, heart rate; HW,
heart weight; IF, Inguinal fat; IVRT, isovolumic relaxation time; LA, left atrium; MCEC, mouse coronary endothelial cell; MMP-2, matrix
metalloproteinase 2; MMP-9, matrix metalloproteinase 9; ns, not significant; PWD, pulse wave Doppler; PWT, posterior wall thickness; RCS, reactive
carbonyl species; ROS, reactive oxygen species; SDS-PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis; siRNA, small interfering
RNA; TL, tibial length; VEGF, vascular endothelial growth factor; WB, Western blot; WT, wild type.
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subsequent decrease in coronary angiogenesis in diabetic mouse heart which was
rescued by ALDH2.
KEYWORDS

4-hydroxy-2-nonenal, adiponectin, aldehyde dehydrogenase 2, AMP-activated protein kinase,
cardioprotection, coronary angiogenesis
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I N T RO DU CT ION

Diabetes mellitus (DM)–
mediated cardiovascular diseases (CVDs) account for two to fourfold higher mortality
in DM patients.1 One of the most common architectural
changes in DM-
induced CVDs is decreased coronary
microvasculature.2,3 Among CVDs caused by DM, heart
failure with preserved ejection fraction (HFpEF) is gaining more attention.4,5 The pathogenesis of HFpEF originates with microvascular inflammation, dysfunction, and
loss.5 A decrease in coronary angiogenesis is one of the
reasons for this reduced coronary microvasculature. DM
leads to the generation of reactive oxygen species (ROS),
reactive carbonyl species (RCS), and reactive nitrogen
species.6 Among the RCS, 4-hydroxy-2-nonenal (4HNE)
is generated upon lipid peroxidation. 4HNE is highly reactive and cytotoxic, which has been implicated in the
pathogenesis of diabetic heart diseases.7 We previously
showed that 4HNE adduct formation is associated with a
decrease in myocardial capillary density in diabetic mice
hearts compared with age-matched wild-type (WT) non-
diabetic control mice.8 Our recent in vitro cell culture
study showed that treatment with 4HNE significantly decreased angiogenesis in cultured mouse coronary endothelial cell (MCEC) lines compared with the control via
reducing the expression of proangiogenic genes.9 Thus,
4HNE-mediated decrease in coronary angiogenesis and
pertaining signaling changes can be an important area to
focus on HFpEF pathogenesis.
4HNE is majorly metabolized by the mitochondrial enzyme, aldehyde dehydrogenase 2 (ALDH2), which is well
known for its cardioprotective role in different types of
cardiac diseases, including heart failure, cardiomyopathy,
and myocardial infarction.6 We and others showed that
ALDH2 renders cardioprotection in DM-mediated heart
disease.8,11 We showed that high-fat-diet-fed diabetic mice
with intrinsic low ALDH2 activity (ALDH2*2 knock-in
mutant mice) exhibited severe HFpEF with exacerbated
diastolic dysfunction and preserved systolic function at
around 6 months compared with their counterparts, that
is, the high-fat-diet fed WT diabetic mice.12 In another
recent study, we reported that type-1 DM decreased coronary angiogenesis in WT mice, which was exacerbated
in ALDH2*2 mutant mice.8 Additionally, we showed that

inhibition of ALDH2 activity with disulfiram (DSF), a
pharmacological inhibitor of ALDH2, exacerbated 4HNE-
mediated decrease in MCEC angiogenesis in vitro.9 While
treating MCECs with Alda-1, a small molecule activator
of ALDH2, it attenuated angiotensin II-mediated decrease
in coronary angiogenesis.13 In summary, all these studies suggest 4HNE decreases coronary angiogenesis, low
ALDH2 activity exacerbates it, and activation of ALDH2
can improve coronary angiogenesis. However, how this
process interacts with other physiological factors and hormones is unknown. In this study, we chose to focus on adiponectin (APN), a pleiotropic hormone secreted primarily
by adipocytes, which was shown to protect heart and vasculature14 and also altered in metabolic conditions, including obesity and diabetes.15,16
APN exerts its action through the activation of two
different types of cell surface receptors, AdipoR1 and
AdipoR2, as well as subsequent activation of downstream
signaling molecules, including adaptor protein phosphotyrosine interacting with PH domain and leucine
zipper (APPL)1/APPL2, AMP-
activated protein kinase
(AMPK), and protein kinase B (PKB/AKT).17,18 Due to
tissue-specific variability in the expression of APN receptors and associated downstream signaling molecules, the
mechanism of APN signaling also varies.17 Therefore, just
determining the systemic levels of APN and associated
signaling is not sufficient to validate the exact pathophysiology of any disease that results from impaired APN function. Organ-specific APN resistance plays an important
role in pathogenesis.17 An in vitro study showed that globular APN treatment in human microvascular endothelial
cells 1 (HMEC-1) significantly increased the proliferation,
migration, and angiogenesis compared with vehicle treatment through the upregulation of proangiogenic genes,
including VEGF, matrix metalloproteinase 2 (MMP-
2),
and MMP-9 via the activation of AdipoR1/AMPK-AKT
signaling pathway.20 Findings from this study suggest that
APN works as a cardioprotective molecule via improving
coronary angiogenesis.
Although the role of low APN level in angiogenesis
has been demonstrated in MI-mediated HF; however,
in chronic HF, despite high levels of APN with the absence of APN function, implicated the prognostic role
of APN resistance.20-22 High-
fat diet manifests APN
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resistance in rats exhibiting a poor fatty acid oxidation
in response to exogenous APN besides displaying low
insulin-stimulated glucose transport.23 Functional APN
resistance on specific tissue types (skeletal muscle) has
been implicated in HF.24 Similarly, the critical role of
downstream signaling of APN in endothelial cells has
been demonstrated in vascular function.25 In one of our
recently published reviews, we depicted the downstream
signaling cascade of APN in vascular ECs where APN
activates its receptors, AdipoR1/AdipoR2, on the EC surface and subsequently activates APPL1, an adaptor protein, followed by the activation of either AMPK or AKT,
finally exerting its cellular response, including increased
angiogenesis.17 Thus, in this study, we planned to test
the role of 4HNE and its metabolizing enzyme, ALDH2
in APN-
mediated coronary angiogenesis. We will determine the effects of 4HNE, ALDH2 inhibitor and activator in APN-mediated coronary angiogenesis in vitro
using cultured CECs. Next, we will determine whether
4HNE afflicts the APN signaling pathways in CECs. We
will also determine the APN signaling changes in cardiac tissue from mice with spontaneous diabetes (db/db
mice) and their congenic controls, db/m mice, ALDH2*2
knock-in mutant mice with intrinsic low ALDH2 activity
(AL mice), and diabetic mice with intrinsic low ALDH2
activity (AF mice).

2
2.1

|

M AT E R IALS AN D M ET H OD S

|

Experimental animal

We employed db/db mouse, a leptin receptor mutant
mouse, exhibiting elevated plasma insulin levels at 10–
14 days, elevated blood glucose levels at 4–8 weeks, and
developing cardiac dysfunction around 16–20 weeks of
age. In our facility, we bred db/db mice and their age-
matched controls, db/m, with C57BL/6 background. We
employed ALDH2*2 E487K knock-
in mutant mouse
(ALDH2*2 mouse or AL mouse) that mimics the E487K
mutation in East Asian carriers. The method for creating ALDH2*2 mouse strain is described elsewhere.28
Additionally, we crossed db/db and ALDH2*2 mice to
generate a new mouse strain that has both diabetes and
intrinsic low ALDH2 activity, which we call AF mouse.
All these mice strains were bred and maintained in the
animal care facility at Henry Ford Health System. At
3 months of age, when the db/db mice exhibited just
diabetes and prior to manifesting cardiac dysfunction,
we measured the body weight (BW), fasting blood sugar
(FBS) levels, and 2-hour postprandial blood sugar (2 hr
PPBS) levels, and subsequently sacrificed the mice for
isolation of the aorta and the cardiac tissue to perform
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biochemical and histopathological studies. Additionally,
we measured the tibial length (TL), inguinal fat weight,
and heart weight of the sacrificed mice. We also euthanized 6-month-old mice when they exhibited HFpEF and
performed all assays that we did on three-month-old mice.
The animal protocols were approved by the Wayne State
University Institutional Animal Care and Use Committee,
which conforms to NIH standards.

2.2

|

Cardiac ultrasound

We used 3%–5% isoflurane to induce anesthesia in our mice
and 1%–2% for maintenance through inhalation. During
image recording, a heart rate of 450–500 bpm was maintained in all mice. For the imaging, we used an echocardiogram (Vevo 3100 micro-
ultrasound imaging system,
VisualSonics, Toronto, Ontario, Canada). To determine
the systolic function of the left ventricle, we measured fractional shortening (FS), ejection fraction (EF), heart rate
(HR), cardiac output (CO), and posterior wall thickness
(PWT) using the M-mode of the echocardiogram. To determine the diastolic function of the left ventricle, we measured the E/A ratio and isovolumic relaxation time (IVRT)
using the pulse wave Doppler (PWD)-mode, the E/E′ ratio
using the tissue Doppler (TD)-mode and left atrial (LA)
area using the 2D-mode of the echocardiogram. The images were analyzed using the Vevo LAB image analysis
software (VisualSonics, Toronto, Ontario, Canada).

2.3

|

Mammalian cell culture

We obtained MCECs from Cedarlane (#CLU510) and cultured the cells according to the protocol stated elsewhere in
this manuscript.9,13 Briefly, we used Dulbecco's Modified
Eagle Medium (DMEM) (GE Life Sciences) supplemented
with 10% fetal bovine serum (FBS) (v/v) and 1% (v/v) penicillin/streptomycin (P/S) for MCECs culture. We grew
MCECs in 100-mm cell culture plates and incubated them
in a humidified incubator set at 37°C with a continuous
supply of 5% CO2. We used 0.05% trypsin/EDTA (GE life
Sciences) to passage the cells. After the fourth passage, we
used MCECs for follow-up experiments, including tube
formation assay, spheroid assay, and isolation of proteins
for Western blot (WB).

2.3.1

|

Treatment protocol 1

To test the dose-dependent role of APN in coronary angiogenesis, we treated MCECs, spheroids, and mouse aortic
rings with DMSO as a vehicle and different doses of APN
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(#18461, NBC), including 1, 10, 20, and 30 ng/μl. Then,
we performed microscopy for tube formation by MCECs,
sprout growth by spheroids, and aortic rings after 2, 48,
and 72 h of APN treatment, respectively (Figure 1A).

2.3.2

|

Treatment protocol 2

To study the role of 4HNE along with the modulation of
ALDH2 activity in APN-induced coronary angiogenesis,

F I G U R E 1 Treatment protocols. (A) Treatment protocol 1. (B) Treatment protocol 2. (C) Treatment protocol 3. (D) Treatment protocol 4.
(E) Treatment protocol 5.
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we treated MCECs, spheroids, and aortic rings with 2.5 μM
disulfiram (DSF), an ALDH2 inhibitor or 10 μM alda1,
an ALDH2 activator for 1 h followed by treatment with
75 μM 4HNE for 1 h and subsequent treatment with 10 ng/
μl APN. We performed microscopy for tube formation by
MCECs or protein extraction from MCECs, sprout growth
by spheroids, and aortic rings after 2, 48, and 72 h of APN
treatment, respectively. We also had individual treatments of DMSO, 4HNE, and APN, and a combination of
4HNE+APN (Figure 1B).

|

2.3.3

Treatment protocol 3

To confirm the role of intrinsic low ALDH2 activity
in APN-
induced increased coronary angiogenesis in
db/db, AL, and AF mice, we treated aortic rings as well as
cardiac tissue isolated from them with 10 ng/μl APN for 72 h
and performed subsequent microscopy for sprout growth
by aortic rings/cardiac tissue fragments (Figure 1C).

|

2.3.4

Treatment protocol 4

To confirm the role of AMPK and AKT in APN-induced
coronary angiogenesis, we treated MCECs, spheroids,
and aortic rings with 10 μM compound C (CC), an effective and well-
known pharmacological inhibitor of
AMPK, or 10 μM API-1, a specific AKT inhibitor for 1 h,
followed by treatment with APN (10 ng/μl) and subsequently microscopy for tube formation by MCECs/
protein extraction for WB analysis, sprout growth by
spheroids and aortic rings after 2, 48, and 72 h of APN
treatment, respectively. We also had individual treatments of DMSO and APN as well as a combination of
CC+APN or API-1+APN (Figure 1D).

|

2.3.5

Treatment protocol 5

To confirm the role of an exogenous increase in ALDH2
activity in APN-
induced coronary angiogenesis in
db/db, AL, and AF mice, we treated aortic rings with alda1
for 24 h followed by the treatment with APN (10 ng/μl)
for 72 h, and we subsequently performed microscopy for
sprout growth by aortic rings. We also performed individual treatments of DMSO, APN, and alda1 (Figure 1E).

2.4

|

Tube formation assay

We performed this functional assay according to our
previously published study.9 Briefly, we seeded 0.1 × 106
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MCECs with DMEM (#D5796, SIGMA) in each well of
a Matrigel-coated 24-well palate. After 1 h, we treated
the cells as per the protocol mentioned elsewhere in the
manuscript (Figure 1). We captured micrographs of tube
formation on Matrigel using a 10× phase-contrast microscope (Olympus IX81). We counted the number of loop/
circle formations under each high-power field (HPF) to
determine angiogenesis using the ImageJ software.

2.5

|

Spheroid assay

For making spheroids (~400 cells/spheroid), we counted
80 000 MCECs using a hemocytometer and diluted them
in 4 ml of DMEM supplemented with 10% FBS, 1% P/S,
and 20% Methocel. We transferred the cell suspension
to a sterile multichannel pipette reservoir. Using an
eight-channel pipette, we pipetted 25 μl of cell suspension as drops onto a 150 mm cell culture plate. To form
spheroids, we incubated the plate upside-down in a humidified incubator set at 37°C with a continuous supply
of 5% CO2 for 24 h. Using a 10 ml serological pipette,
we washed off the hanging drops containing the spheroids with 10 ml PBS by pipetting them up and down.
We transferred the spheroid suspension to a 15 ml conical tube and centrifuged it at 200 g for 5 min. We aspirated the supernatant and added 2 ml ice-cold Methocel
containing 20% FBS. Separately we prepared a 4 ml collagen stock solution by adding 1 mg/ml collagen in ice-
cold DMEM supplemented with 10% FBS, 1% P/S, and
30 ng/ml VEGF (#493-MV, R&D Systems). We adjusted
the pH of the collagen stock solution by adding 5 μl of
5 N NaOH and subsequently determined the adjusted
pH through the color change from yellow to orange.
We mixed ice-cold Methocel containing the spheroids
with collagen stock solution and subsequently pipetted
250 μl of collagen stock containing the spheroids in each
well of a 24-well cell culture plate. We incubated the
plates containing the spheroids in a humidified incubator at 37°C with a continuous supply of 5% CO2 for
1 h to solidify the collagen bed due to polymerization.
We added 250 μl of DMEM supplemented with 10% FBS,
1% P/S, and 30 ng/ml VEGF in each well of the 24-well
plate containing the collagen bed with spheroids embedded in it and subsequently incubated in a humidified incubator at 37°C with a continuous supply of 5%
CO2 for 1 h. Then we treated the spheroids according to
the protocol we discussed elsewhere in this manuscript
(Figure 1). We captured images of sprout growth from
the spheroids embedded in the collagen matrix using a
10× phase-contrast microscope. We counted the number of nodes in a sprouted spheroid under HPF to determine angiogenesis using the ImageJ software.

6 of 25

|

2.6

|

Aortic ring assay

We performed the aortic ring assay according to the protocol mentioned elsewhere.27 Briefly, we isolated the
aorta from 16-week-old WT mice and washed them with
sterilized PBS to remove residual blood. Under a surgical microscope, we removed residual fats from the aorta
using sterilized tweezers and washed them with PBS. We
also removed the side branches from the aorta using a
sharp and sterilized scalpel and immediately transferred
the cleaned aorta to a 100-mm plate containing fresh
Opti-
MEM (#51985–
034, ThermoFisher Scientific).
Using a sharp and sterile scalpel, we dissected the aorta
into small ring-
like fragments with an approximate
length of 1 mm. From a single aorta, we made 28–34
aortic rings. Using a sterile sharp-tipped tweezer, we
transferred the aortic rings to a new 60 mm/6-well plate
containing DMEM supplemented with 0.2% FBS and 1%
P/S. We incubated the plates containing the aortic rings
overnight in a humidified incubator set at 37°C with a
continuous supply of 5% CO2. For making collagen stock
solution, we added 1 mg/ml collagen in ice-cold Opti-
MEM supplemented with 10% FBS and 30 ng/ml VEGF.
We pipetted 200 μl of the collagen stock into each well
of a 24-well plate and subsequently planted three aortic
rings in each well on the top of the collagen bed using a
sharp-tipped sterile tweezer. We planted the aortic rings
on the collagen bed so that the luminal axis is perpendicular to the bottom of the well. Then, we incubated the
plate in a humidified incubator set at 37°C with a continuous supply of 5% CO2 for 1 h to solidify the collagen bed
due to polymerization. We added 100 μl of collagen stock
in each well on the top of the aortic rings to embed them
into the collagen bed. We incubated the plate in a humidified incubator set at 37°C with a continuous supply
of 5% CO2 for 1 h and subsequently added 250 μl of Opti-
MEM supplemented with 10% FBS and 30 ng/ml VEGF
in each well of 24-well plate containing the collagen bed
with aortic rings embedded in it. Then we treated the
aortic rings according to the protocol we discussed elsewhere in the manuscript (Figure 1). We captured images
of sprout growth from the aortic rings embedded in the
collagen matrix using a 10× phase-contrast microscope.
We measured the relative sprouting area (%) from each
aortic ring under HPF to determine angiogenesis using
the ImageJ software.

2.7

|
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Cardiac tissue sprouting assay

Briefly, we isolated the hearts from 16-week-old db/m,
db/db, AL, and AF mice and washed them with sterilized

PBS to remove residual blood. Under a surgical microscope, we removed residual fats from the hearts using
sterilized tweezers and washed them with sterilized PBS.
We cut the cardiac tissue into four or five large fragments
using a sharp and sterilized scalpel and subsequently
washed the cardiac tissue fragments with sterilized PBS.
Immediately we transferred the cleaned cardiac tissue
fragments to a sterilized 100 mm plate containing fresh
Opti-MEM (#51985–034, ThermoFisher Scientific). Using
a sharp and sterilized scalpel, we dissected the large cardiac tissue fragments into tiny fragments of random sizes.
Using a sterile sharp-tipped tweezer, we transferred the
small cardiac tissue fragments to a new 6-well plate containing DMEM supplemented with 0.2% FBS and 1% P/S.
We incubated the plates containing the cardiac tissue fragments overnight in a humidified incubator at 37°C with a
continuous supply of 5% CO2. For making collagen stock
solution, we added 1 mg/ml collagen in ice-cold Opti-
MEM supplemented with 10% FBS and 30 ng/ml VEGF.
We pipetted 200 μl of the collagen stock into each well of
a 24-well plate and subsequently planted three cardiac tissue fragments in each well on the top of the collagen bed
using a sharp-tipped sterile tweezer. Then, we incubated
the plate in a humidified incubator at 37°C with a continuous supply of 5% CO2 for 1 h to solidify the collagen bed
due to polymerization. We added 100 μl of collagen stock
in each well on the top of the cardiac tissue fragments to
embed them into the collagen matrix. We incubated the
plate in a humidified incubator at 37°C with a continuous
supply of 5% CO2 for 1 h and subsequently added 250 μl
of Opti-MEM supplemented with 10% FBS and 30 ng/ml
VEGF in each well of the 24-well plate containing the collagen matrix with cardiac tissue fragments embedded in
it. Then we treated the cardiac tissue fragments according
to the protocol we discussed elsewhere in the manuscript
(Figure 1). We captured images of sprout growth from the
cardiac tissue fragments embedded in the collagen matrix using a 10× phase-contrast microscope. We measured
the relative sprouting area (%) from each cardiac tissue
fragment under HPF to determine angiogenesis using the
ImageJ software.

2.8 | Measurement of
biometric parameters
To normalize the cardiac parameters in mice, we measured the ratios of BW/TL and HW/TL. We measured the
TL from the sacrificed mice using a Vernier caliper along
with the weight of the body and hearts. We also measured
the IF weight from the sacrificed mice to determine the
IF/BW, an indicator of dyslipidemia.
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2.9 | Measurement of metabolic
parameters
2.9.1 | Enzyme-linked
immunosorbent assays
To determine serum APN, insulin, and leptin levels in
mice, we performed the enzyme-linked immunosorbent
assay (ELISA) according to the manufacturer's protocol
(#80569, #90080, and #90030, Crystal Chem, respectively).

2.9.2

|

Intraperitoneal glucose tolerance test

To measure FBS and 2 hr PPBS, we performed the
Intraperitoneal glucose tolerance test according to the
protocol mentioned elsewhere.28 Briefly, after fasting for
6 h, the mice were subjected to an intraperitoneal injection with 1 g/kg d-glucose. Then blood glucose levels were
measured at 0, 30, 60, 90, and 120 min after d-glucose injection using a glucometer.

2.10

|

Western immunoblotting

To determine the protein levels of APN and its downstream signaling molecules, including AdipoR1, AdipoR2,
APPL1, AMPK, phospho-
AMPK, AKT, and phosphor-
AKT, we performed Western blotting using total proteins
from MCECs lysate or mouse whole cardiac tissue lysate.
We extracted proteins from MCECs or mouse cardiac tissue using tissue protein extraction reagents (Thermofisher
Scientific) containing protease/phosphatase inhibitors.
Using the Bradford protein assay, we determined the
total protein concentrations. We separated the specific
protein bands using SDS-PAGE and subsequently transferred the bands to nitrocellulose membranes. We blocked
the membranes using 5% bovine serum albumin (BSA)
(#9048-
46-
8, Millipore Sigma) and subsequently incubated the membranes with APN rabbit mAb (#2789, CST),
AdipoR1 rabbit mAb (#ab126611, AB), AdipoR2 mouse
mAb (#514045, SCB), APPL1 rabbit mAb (#3858, CST),
AMPK rabbit mAb (#2603, CST), phospho-AMPK rabbit
mAb (#2535, CST), AKT rabbit mAb (#9272, CST), and
phosphor-AKT (#4060, CST).

2.11

|

Statistical analysis

To determine statistical significance between two groups,
we performed the student t-test and one-way/two-way
ANOVA followed by the Tukey post hoc test for multiple groups analysis using GraphPad Prism 9.2.0.332
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(GraphPad Software). We compiled the experimental data
and calculated the means and standard error of the means
(SEM) using excel spreadsheets. We considered the level
of significance at <.05.

3

|

RESULTS

3.1 | APN increases coronary
angiogenesis in mouse
APN-treatment, 1 ng/μl, did not increase angiogenesis as
indicated by the number of circle counts in MCECs compared with the control (Figure 2A–C,S). However, 10, 20
and 30 ng/μl APN-treated MCECs significantly increased
tube formation compared with the control (p = .002,
<.0001 and < .0001 vs. control for 10, 20 and 30 ng/μl
APN, respectively) as well as 1 ng/μl APN-treated MCECs
(p = .01, .0002 and <.0001 for 10, 20 and 30 ng/μl APN,
respectively) (Figure 2A–F,S). To reconfirm the role of
APN in coronary angiogenesis, we performed spheroid
and aortic ring assays. Data from the spheroid assay
showed that 1 ng/μl APN-treated spheroids did not increase angiogenesis on collagen matrix as indicated by
the number of nodes in each spheroid compared with the
control (Figure 2G–I,T). However, 10, 20, and 30 ng/μl
APN-treated spheroids significantly increased angiogenesis compared with the control (p = .04, .02, and .004 for
10, 20, and 30 ng/μl APN, respectively) (Figure 2G,H,J–
L,T). Similarly, the aortic ring assay data also showed that
1 ng/μl APN-treated aortic rings did not increase angiogenesis on collagen matrix as indicated by the percentage
of sprouting area in each aortic ring compared with the
control (Figure 2M–O,U). However, there is a significant
increase in sprouting area in 10, 20, and 30 ng/μl APN-
treated aortic rings compared with the control (p = .01,
.005, and .0006 for 10, 20, and 30 ng/μl APN, respectively)
(Figure 2M,N,P–R,U).

3.2 | 4HNE attenuates APN-induced
increased coronary angiogenesis, which is
exacerbated with ALDH2 inhibition and
rescued with ALDH2 activation
APN treatments significantly increased angiogenesis
compared with controls in all three assays (p = .04, .002,
and .0006 for tube formation, spheroid, and aortic ring
assays, respectively) (Figure 3A,C,H,J,O,Q,V,W,X),
whereas 4HNE treatment significantly decreased angiogenesis compared with their controls (p = .04, .002,
and .02 for tube formation, spheroid, and aortic ring assays, respectively) (Figure 3A,D,H,K,O, R,V,W,X). 4HNE
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F I G U R E 2 Dose-dependent effect of APN in coronary angiogenesis. (A–F) Representative micrographs of tube formation on Matrigel
by control, DMSO, 1, 10, 20, and 30 ng/μl APN treated MCECs for 2 h. Magnification: 10×. (G–L) Representative micrographs of sprout
formation by control, DMSO, 1, 10, 20, and 30 ng/μl APN treated spheroids on collagen for 24 h. Magnification: 10×. (M–R) Representative
micrographs of sprout formation by control (WT), DMSO, 1, 10, 20, and 30 ng/μl APN treated aortic rings on a collagen matrix for 72 h.
Magnification: 10×. (S) Quantitative data of circle counts/HPF with different treatments stated in A through F. N = 6 for each group. Each
bar represents the mean ± SEM. p value <.0001 among the groups. (T) Quantitative data of node counts/spheroid with different treatments
stated in G through L. n = 7 for each group. Each bar represents the mean ± SEM. p value = .001 among the groups. (U) Quantitative data of
sprouting area/aortic ring with different treatments stated in M through R. N = 6 for each group. Each bar represents the mean ± SEM.
p value <.0001 among the groups. APN, adiponectin; DMSO, dimethyl sulfoxide; HPF, high power field; ns, not significant. The control and
DMSO did not have any difference in any of the three assays. Thus, we only presented the statistical difference between control and APN
treatments to keep it less crowded.

pretreatment before APN challenge significantly decreased angiogenesis compared with APN alone (p = .04,
.009, and .002 for tube formation, spheroid, and aortic
ring assays, respectively) (Figure 3C,E,J,L,Q,S,V,W,X).

DSF pretreatment before 4HNE challenge exacerbated
the 4HNE-
mediated downregulation of APN-
induced
increase in angiogenesis (p = .04, .01, and .05 for tube
formation, spheroid, and aortic ring assays, respectively)
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F I G U R E 3 Role of 4HNE and/or modulation of ALDH2 activity in APN-induced increased angiogenesis. (A–G) Representative
micrographs of tube formation on Matrigel by control, DMSO, adiponectin (10 ng/μl), 4HNE (75 μM), 4HNE+adiponectin,
DSF+4HNE+adiponectin, and alda1+4HNE+adiponectin treated MCECs for 2 h, respectively. Magnification: 10×. (H–N) Representative
micrographs of sprout formation by control, DMSO, adiponectin (10 ng/μl), 4HNE (75 μM), 4HNE+adiponectin, DSF+4HNE+adiponectin,
and alda1+4HNE+adiponectin treated spheroids on collagen for 24 h, respectively. Magnification: 10×. (O–U) Representative micrographs
of sprout formation by control, DMSO, adiponectin (10 ng/μl), 4HNE (75 μM), 4HNE+adiponectin, DSF+4HNE+adiponectin, and
alda1+4HNE+adiponectin treated aortic rings on collagen matrix for 72 h, respectively. Magnification: 10×. (V) Quantitative data of circle
counts/HPF with different treatments stated in A through G. N = 6 for each group. Each bar represents the mean ± SEM. p value <.0001
among the groups. (W) Quantitative data of node counts/spheroid with different treatments stated in I through O. n = 6 for each group.
Each bar represents the mean ± SEM. p value = .001 among the groups. (X) Quantitative data of sprouting area/aortic ring with different
treatments stated in Q through Q. N = 7 for each group. Each bar represents the mean ± SEM. p value <.0001 among the groups. 4HNE,
4-hydroxy-2-nonenal; APN, adiponectin; DMSO, dimethyl sulfoxide; DSF, disulfiram; HPF, high power field; ns, not significant.

(Figure 3E,F,L,M,S,T,V,W,X), whereas alda1 pretreatment before 4HNE challenge rescued the 4HNE-
mediated downregulation of APN-
induced increase

in angiogenesis (p = .02 and .04 vs. 4HNE+APN for
tube formation and aortic ring assays, respectively)
(Figure 3E,G,S,U,V,X).
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3.3 | Altered ALDH2 activity by
pharmacological modulators alters
APN signaling in mouse coronary
endothelial cells
Our previous study showed that modulation of ALDH2
activity by pharmacological modulators in MCECs plays
an important role in MCECs angiogenesis in vitro.9,10,13
To study the role of ALDH2 on APN signaling in MCECs,
we performed WB using total protein from 4HNE (75 μM)
along with DSF (2.5 μM)/Alda1 (10 μM) treated MCECs
lysates (Figure 4).
Our WB data showed that 4HNE-treated MCECs significantly decreased AdipoR1 protein levels compared
with the control (p = .02) (Figure 4A,B). However, DSF or
alda1-treated MCECs did not significantly change adipoR1
protein levels compared with the control (Figure 4A,B).
DSF pretreatment before the 4HNE challenge exacerbated the 4HNE-mediated decrease in adipoR1 protein
levels in MCECs (p = .007 vs. 4HNE and p = .0001 vs.
DSF) (Figure 4A,B). Alda-1 pretreatment rescued 4HNE-
mediated decrease in adipoR1 protein levels in MCECs
(p = .006 vs. 4HNE) (Figure 4A,B). Alda-1 pretreatment
rescued DSF+4HNE-mediated decrease in adipoR1 protein levels in MCECs (.0001 vs. DSF+4HNE).
4HNE-
treated MCECs significantly decreased adipoR2 protein levels compared with the control (p = .02)
(Figure 4A,C). However, DSF and alda1-treated MCECs
did not significantly change adipoR2 protein levels compared with the control (Figure 4A,C). DSF or alda1 pretreatments did not affect the 4HNE-mediated decrease in
adipoR2 levels in MCECs (Figure 4A,C). 4HNE-treated
MCECs significantly decreased APPL1 protein levels relative to control (p = .02) (Figure 4A,D). Similarly, DSF-
treated MCECs showed a significant decrease in APPL1
protein levels relative to control (p = .03) (Figure 4A,D).
However, alda1-
treated MCECs did not significantly
change APPL1 protein levels compared with the control
(Figure 4A,D). DSF pretreatment before 4HNE challenge
exacerbated the 4HNE-mediated decrease in APPL1 protein levels in MCECs (p = .04 vs. 4HNE and p = .02 vs.
DSF) (Figure 4A,D). Alda1 pretreatment before 4HNE
and DSF+4HNE challenges rescued the 4HNE-mediated
and the DSF+4HNE-mediated decrease in APPL1 protein
levels in MCECs (p = .02 vs. both 4HNE and DSF, and
p < .0001 vs. DSF+4HNE) (Figure 4A,D). 4HNE-treated
MCECs showed a significant decrease in AMPK, P-AMPK
protein levels as well as the P-AMPK/AMPK ratio compared with their controls (p = .007, <.0001, and .002 for
AMPK, P-
AMPK, and P-
AMPK/AMPK, respectively)
(Figure 4A,E–G). Similarly, DSF-treated MCECs showed
a significant decrease in AMPK, P-AMPK protein levels
as well as the P-AMPK/AMPK ratio compared with their
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controls (p = .04, .005, and .05 for AMPK, P-AMPK, and
P-
AMPK/AMPK, respectively) (Figure 4A,E–G). DSF
pretreatment before 4HNE challenge exacerbated the
4HNE-
mediated decreases in AMPK, P-
AMPK protein
levels as well as the P-AMPK/AMPK ratio compared with
4HNE alone (p = .003, .002, and .04 for AMPK, P-AMPK
and P-
AMPK/AMPK, respectively) (Figure 4A,E–G).
Alda1 pretreatment before 4HNE challenge rescued the
4HNE-
mediated decreases in AMPK, P-
AMPK protein
levels as well as the P-
AMPK/AMPK ratio compared
with 4HNE alone (p = .01, .002, and .003 for AMPK,
P-
AMPK,
and
P-
AMPK/AMPK,
respectively)
(Figure 4A,E–G). Additionally, alda1 pretreatment rescued
the DSF+4HNE-mediated decreases in AMPK, P-AMPK
as well as P-AMPK/AMPK ratio compared with 4HNE
alone (p = .0001, .0001, and .0002 for AMPK, P-AMPK,
and P-
AMPK/AMPK, respectively) (Figure 4A,E–G).
4HNE-
treated MCECs did not show any significant
change in AKT protein levels relative to control, whereas
P-AKT protein levels, as well as the P-AKT/AKT ratio
significantly decreased in 4HNE-treated MCECs (p = .03
and .04 for P-
AKT, and P-
AKT/AKT, respectively)
(Figure 4A,H-J). However, there is no significant change
in the protein levels of AKT and P-AKT, as well as the P-
AKT/AKT ratio in DSF-treated MCECs (Figure 4A,H-J).
DSF pretreatment before the 4HNE challenge did not
significantly change the levels of AKT protein in MCECs
compared with 4HNE alone, whereas DSF pretreatment
before the 4HNE challenge significantly decreased the
protein levels of P-AKT as well as the P-AKT/AKT ratio
in MCECs compared with 4HNE alone (p = .04 and .03
for P-KT and P-AKT/AKT, respectively) (Figure 4A,H–J).
Alda1 pretreatment before the 4HNE challenge did not
show any significant increase in AKT protein levels compared with 4HNE alone, whereas Alda1 pretreatment
before the 4HNE challenge rescued the 4HNE-mediated
decrease in P-AKT protein levels as well as the P-AKT/
AKT ratio compared with 4HNE alone (p = .03 and .05 for
P-AKT and P-AKT/AKT, respectively) (Figure 4A,H–J).
Alda1 pretreatment before DSF+4HNE challenge improved DSF+ 4HNE-mediated decreases in P-AKT and P-
AKT/AKT but not in AKT (p = .0001 and .002 for P-AKT
and P-AKT/AKT, respectively) (Figure 4A,H–J).

3.4 | db/db and AF mice exhibit HFpEF
by showing diastolic dysfunction with a
preserved systolic function at 6-month-old
compared with 3-month-old
We found a significant impairment in diastolic function,
including E/A ratio, E/E′ ratio, IVRT and LA area in
db/db mice at 6 months compared with 3 months, when
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F I G U R E 4 Impaired levels of AdipoR1, AdipoR2, APPL1, P-AMPK, and P-AKT in 4HNE treatment along with pharmacological
modulation of ALDH2 in cultured MCECs. (A) Representative Western blot (WB) band images of AdipoR1, AdipoR2, APPL1, AMPK,
P-AMPK, AKT, P-AKT, and GAPDH proteins in MCECs after 1 h of DSF (2.5 μM)/Alda1 (10 μM) treatments followed by 2 h of 4HNE
(75 μM) treatment. (B) Quantification of WB data of AdipoR1 protein levels stated in panel A. N = 6 for each group, each bar represents the
mean ± SEM, p value = .0002 among the groups. (C) Quantification of WB data of AdipoR2 protein levels stated in panel A. N = 6 for each
group, each bar represents the mean ± SEM, p value = .0041 among the groups. (D) Quantification of WB data of APPL1 protein levels stated
in panel A. N = 6 for each group, each bar represents the mean ± SEM, p value <.0001 among the groups. (E) Quantification of WB data of
AMPK protein levels stated in panel A. N = 6 for each group, each bar represents the mean ± SEM, p value <.0001 among the groups. (F)
Quantification of WB data of P-AMPK protein levels stated in panel A. N = 6 for each group. Each bar represents the mean ± SEM,
p value <.0001 among the groups. (G) The ratio of P-AMPK and AMPK levels stated in panels F and E, respectively, each bar represents the
mean ± SEM, p value <.0001 among the groups. (H) Quantification of WB data of AKT protein levels stated in panel A. N = 6 for each group,
each bar represents the mean ± SEM, p value <.0001 among the groups. (I) Quantification of WB data of P-AKT protein levels stated in panel
A. N = 6 for each group. Each bar represents the mean ± SEM, p value <.0001 among the groups. (J) The ratio of the P-AKT and AKT levels
stated in panels I and H, respectively. Each bar represents the mean ± SEM, p value <.0001 among the groups. A, alda1; D, disulfiram; ns,
not significant.

the systolic function, including FS, EF, HR, CO/BW ratio
and PWT are preserved, suggesting they manifest HFpEF
(Table 1). When we checked the cardiac function at
6 months in AF mice, we found that the diastolic dysfunction further deteriorated in them compared with db/db
mice (Table 2).

3.5 | Biometric and metabolic factors
altered in the db/db and AF mice
Db/db and AF mice showed a significant increase in
their BW and decreased HW/BW ratio compared with
their db/m controls (Table 3). TL and the HW/TL ratio
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Parameters (unit)

db/m, 3 M

db/db 3 M

db/m, 6 M

FS (%)

36.9 ± 3.8

36.9 ± 9.5

38.4 ± 9.5

39.4 ± 13.6

EF (%)

70.8 ± 5.8

69.7 ± 12.2

71.4 ± 12.2

68.3 ± 17.4

HR (Bmp)

422.8 ± 6.0

428.8 ± 23.2

449.3 ± 69.3

CO/BW (ml/min/g)

0.66 ± 0.13

0.51 ± 0.23

0.61 ± 0.10

0.45 ± 0.13

PWT (mm)

0.62 ± 0.05

0.66 ± 0.06

0.66 ± 0.14

0.75 ± 0.08

E/A ratio

1.73 ± 0.33

1.36 ± 0.17

2.38 ± 0.43

0.99 ± 0.57*

E/E′ ratio

22.4 ± 3.0

28.2 ± 7.0

29.8 ± 5.5

49.8 ± 4.6*¤

8.5 ± 1.6

12.2 ± 3.3

7.8 ± 1.9

19.4 ± 5.2*¤

1.8 ± 0.4

3.4 ± 0.6*¤

IVRT (ms)
2

LA area (mm )

1.9 ± 0.2

419.3 ± 8.0

db/db 6 M

2.6 ± 0.4

*

T A B L E 1 Echocardiographic
measurements in db/m and db/db at 3
and 6 M, (n = 4)

Abbreviations: BW, body weight; CO, cardiac output; EF, ejection fraction; FS, fractional shortening; HR,
heart rate; IVRT, isovolumic relaxation time; LA, left atrium; PWT, posterior wall thickness.
*p < .05 versus db/m; ¤p < .05 versus 3 M.

Parameters
(unit)

db/m

db/db

AL

AF

FS (%)

38.4 ± 9.5

39.4 ± 13.6

45.6 ± 7.1

40.8 ± 3.5

EF (%)

71.4 ± 12.2

68.3 ± 17.4

77.1 ± 7.1

71.9 ± 4.2

428.8 ± 23.2

449.3 ± 69.3

422.8 ± 86.5

379.8 ± 53.9

CO/BW (ml/
min/g)

HR (Bmp)

0.61 ± 0.10

0.45 ± 0.13

0.66 ± 0.14

0.31 ± 0.04¤

PWT (mm)

0.66 ± 0.14

0.75 ± 0.08

0.92 ± 0.22

1.06 ± 0.23

E/A ratio

2.38 ± 0.43

0.99 ± 0.57*

1.38 ± 0.93

0.93 ± 0.29

E/E' ratio

29.8 ± 5.5

49.8 ± 4.6*

31.3 ± 0.9

50.6 ± 7.6¤

7.8 ± 1.9

19.4 ± 5.2*

12.8 ± 5.8

28.8 ± 3.1#¤

1.8 ± 0.4

3.4 ± 0.6*

IVRT (ms)
2

LA area (mm )

2.7 ± 0.4*

T A B L E 2 Echocardiographic
measurements in db/m, db/db, AL, and
AF mice at 6 M (n = 4)

4.4 ± 0.8#¤

Abbreviations: BW, body weight; CO, cardiac output; EF, ejection fraction; FS, fractional shortening; HR,
heart rate; IVRT, isovolumic relaxation time; LA, left atrium; PWT, posterior wall thickness.
*p < .05 versus db/m; ¤p < .05 versus AL; #p < .05 versus db/db.

significantly decreased, whereas the BW/TL ratio significantly increased in db/db and AF mice compared with
their db/m controls (Table 3). The IF and the IF/BW ratio
significantly increased in db/db and AF mice compared
with their db/m controls (Table 3). Several metabolic factors, including the FBS, 2 hr PPBS, insulin, and leptin levels, increased significantly in the serum of db/db and AF
mice (Table 3).

3.6 | Mice with low ALDH2 activity
exhibit reduced coronary angiogenesis due
to poor APN response
To study the role of exogenous APN in coronary angiogenesis in genetically modified mice with intrinsically

low ALDH2 activity, that is, AL and AF mice and
diabetes-
induced decreased ALDH2 activity, that is,
db/db mice and their control db/db mice, we treated
the aortic rings isolated from them with 10 ng/μl
APN. Our analysis and quantification showed that at
3 months, APN treatment significantly increased angiogenesis in both db/m and db/db mice aortic rings
compared with their controls without APN treatment
(p < .0001 and .004 in db/m and db/db, respectively)
(Figure 5A,B,E,F,I). However, there was no significant
increase in angiogenesis in 3-month-old AL and AF mice
aortic rings with APN treatment compared with their
controls without APN treatment (Figure 5C,D,G–I).
When we treated the cardiac tissue fragments isolated from 3-month-old db/m, db/db, AL and AF mice
with APN (Figure S1), our results showed that APN
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T A B L E 3 Biometric and metabolic
factors in db/m, db/db, AL, and AF mice
at 6 M (n = 4)

  

Parameters (unit)
BW (g)
HW (mg)
HW/BW (mg/g)
TL (mm)
BW/TL (g/mm)
HW/TL (mg/mm)

db/m
33.3 ± 0.5
170.0 ± 1.6
5.1 ± 0.5

db/db
48.7 ± 7.1*
136.6 ± 2.1
2.9 ± 0.5*

AL
30.7 ± 2.9

|
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AF
#

54.0 ± 5.8*#¤

164.0 ± 5.3

180.8 ± 8.2

5.3 ± 1.3

#

3.3 ± 1.2*¤

18.2 ± 0.1

#

17.1 ± 0.2*¤
3.2 ± 0.4*¤

18.2 ± 0.4

17.3 ± 0.2*

1.8 ± 0.3

2.8 ± 0.4*

1.7 ± 0.2#

92.8 ± 8.9

49.5 ± 12.0*

96.1 ± 24.3#
#

IF (g)

0.44 ± 0.13

2.49 ± 0.51*

0.60 ± 0.04

IF/BW (mg/g)

13.3 ± 4.0

52.0 ± 13.1*

19.6 ± 6.1#

55.3 ± 19.0*¤
4.10 ± 0.75*#¤
77.6 ± 21.4*#¤

FBS (mg/dl)

159.6 ± 9.3

238.0 ± 39.9

189.4 ± 21.5

336.6 ± 22.7*¤

2 hr PPBS (mg/dl)

179.0 ± 11.8

362.4 ± 70.2*

168.8 ± 16.3#

467.2 ± 44.4*#¤

0.75 ± 0.07

6.53 ± 0.76*

0.71 ± 0.08#

6.90 ± 0.35*#

Insulin (ng/ml)
Leptin (ng/ml)

31.3 ± 9.8

59.4 ± 4.8*

28.5 ± 4.8

#

66.4 ± 10.7*#

Abbreviations: 2 hr PPBS, 2-hour postprandial blood sugar; BW, body weight; FBS, fasting blood sugar;
HW, heart weight; IF, inguinal fat; TL, tibial length.
*p < .05 versus db/m; ¤p < .05 versus AL; #p < .05 versus db/db.

treatment significantly increased cardiac angiogenesis
in both db/m and db/db mice compared with their controls without APN treatment (p = .001 and .005 in db/m
and db/db, respectively) (Figure S1). However, there
was no significant increase in angiogenesis in cardiac
tissue from 3-month-old AL and AF mice with APN
treatment relative to their controls, without APN treatment (Figure S1). At 6 months, APN treatment significantly increased angiogenesis in only the aortic rings of
db/m mice compared with their controls without APN
treatment (p = .05) (Figure 5J,N,R), but not in corresponding aortic rings of 6-month-old db/db, AL and AF
mice (Figure 5K-M,O-R).

3.7 | Intrinsic low ALDH2 activity in
AF mice increases serum APN levels at
6 months
When we checked the serum APN levels in 3-month-old
db/db and AF mice when they did not exhibit HFpEF,
there was no significant change in the serum APN levels in db/db, AL, and AF mice compared with db/m
control mice (Figure 6A). However, the serum APN
levels significantly increased in AL and AF mice compared with the db/m control (p = .05 and .004 for AL
and AF, respectively) (Figure 6B). Most importantly,
the serum APN levels increased significantly in the
AF mouse compared with the db/db mouse (p = .05)
(Figure 6B).

3.8 | Decreased ALDH2 activity
downregulates APN signaling in db/db and
AF mouse hearts
To study the role of low intrinsic ALDH2 activity on APN
signaling in our experimental mouse hearts, we performed
WB using total protein from 3-month-old and 6-month-old
db/m, db/db, AL, and AF mouse hearts (Figure 7).
The WB data showed that APN protein levels were
significantly decreased in both 3-month and 6-month db/
db mouse hearts compared with their age-matched db/m
controls (p = .002 and .003 for 3 months and 6 months,
respectively) (Figure 7A–C). However, there was no significant change in APN protein levels in 3-month-old and
6-month-old AL mouse cardiac tissues compared with their
age-matched db/m controls (Figure 7A–C). 3-month-old
AF mouse heart showed a significant reduction in APN
protein levels compared with their age-matched db/m control (p = .04), whereas there was no significant difference
in cardiac APN protein levels between 6-month-old-AF
and db/m control mice (Figure 7A–C).
A significant decrease in cardiac adipoR1 protein
levels in both 3-
month-
old and 6-
month-
old db/db
mice compared with their age-matched db/m controls
(p = .04 and <.0001 for 3 months and 6 months, respectively) (Figure 7A,B,D) was found. However, adipoR1
protein levels were not different in the heart tissue of AL
mice compared with db/m controls in both age groups
(Figure 7A,B,D). In both 3-month-old and 6-month-old
AF mice, a significant reduction in cardiac adipoR1
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F I G U R E 5 Role of exogenous APN in coronary angiogenesis of db/m, db/db, AL and AF mice. (A–D) Representative micrographs
of sprout formation by 3-month-old db/m, db/db, AL, and AF mice aortic rings on collagen matrix after 72 h. (E–H) Representative
micrographs of sprout formation by 3-month-old db/m, db/db, AL and AF mice aortic rings on collagen matrix with adiponectin treatment
after 72 h. Magnification: 10×. (I) Quantitative data of sprouting area/aortic ring stated in A through H. N = 6 for each group. Each bar
represents the mean ± SEM. (J–M) Representative micrographs of sprout formation by 6-month-old db/m, db/db, AL, and AF mice aortic
rings on collagen matrix after 72 h. (N–Q) Representative micrographs of sprout formation by 6-month-old db/m, db/db, AL, and AF mice
aortic rings on a collagen matrix with adiponectin treatment after 72 h. Magnification: 10×. (R) Quantitative data of sprouting area/aortic
ring stated in panels J through Q. N = 7 to 8 for each group. Each bar represents the mean ± SEM. APN, adiponectin; HPF, high power field;
3 m, 3 months; 6 m, 6 months and ns, not significant.

protein levels was observed compared with their age-
matched db/db mice as well as other groups (p = .05 vs.
db/db at both 3 months and 6 months) (Figure 7A,B,D).
Additionally, a significant reduction in cardiac tissue adipoR1 levels at 6-month-old db/db and AF mice
was found compared with their 3-month-old counterparts. (p = .009 and .05 for db/db and AF, respectively)
(Figure 7A,B,D).
There was no significant difference in AdipoR2 protein levels in 3-
month-
old db/db mouse cardiac tissue compared with their age-
matched db/m control
(Figure 7A,B,E). However, AdipoR2 protein levels were
decreased significantly in 6-
month-
old db/db mouse
cardiac tissue compared with their age-matched db/m
control (p < .0001) (Figure 7A,B,E). AdipoR2 protein
levels were decreased significantly in both 3-month-old
and 6-month-old AL mice cardiac tissue compared with
their age-
matched db/m controls (p < .0001 for both
3 months and 6 months). There was no significant difference in AdipoR2 protein levels in 3-
month-
old AF

mouse cardiac tissue compared with their age-matched
db/m control and db/db mice (Figure 7A,B,E). However,
AdipoR2 protein levels were significantly decreased in
6-
month-
old AF mouse cardiac tissue compared with
their age-matched, control db/m mice, as well as db/db
mice (p < .0001 vs. db/m and p = .002 vs. db/db mice)
(Figure 7A,B,E). In both db/db and AF mouse cardiac tissue, we found a significant reduction in AdipoR2 protein
levels at 6 months compared with 3 months (p = .04 and
<.0001 for db/db and AF, respectively) (Figure 7A,B,E).
A significant decrease in APPL1 protein levels was found
in both 3-month-old and 6-month-old db/db mice cardiac
tissue compared with their age-matched db/m (p = .05
for both 3 months and 6 months mice) (Figure 7A,B,F).
However, no significant difference in cardiac APPL1
protein levels was observed in both 3-
month-
old and
6-month-old AL mice compared with their age-matched
db/m controls (Figure 7A,B,F). A significant reduction in
APPL1 protein levels was found in both 3-month-old and
6-month-old AF mouse cardiac tissues compared with
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F I G U R E 6 Serum APN levels in 3-month-old and 6-month-old db/m, db/db, AL, and AF mice. (A) Serum adiponectin protein levels at
3-month-old db/m, db/db, AL, and AF mice were determined through ELISA. N = 6 for each group, each bar represents the mean ± SEM.
(B) Serum adiponectin protein levels at 6-month-old db/m, db/db, AL, and AF mice were determined through ELISA. N = 5–7 for each
group, each bar represents the mean ± SEM. 3 m, 3 months; 6 m, 6 months; and ns, not significant.

their age-matched db/db mouse cardiac tissues (p = .03
and <.0001 vs. db/db at 3 months and 6 months, respectively) (Figure 7A,B,F). AF mouse cardiac tissue significantly reduced APPL1 levels at 6 months compared with
3 months (p = .05) (Figure 7A,B,F).
There is a significant reduction in both AMPK and
P-AMPK protein levels as well as the P-AMPK/AMPK
ratio in 3-
month-
old and 6-
month-
old db/db mouse
cardiac tissue compared with their age-matched db/m
controls (p = .04 and .004 for AMPK at 3-month-old
and 6-month-old mice, respectively, p = .04 and .003
for P-AMPK at 3-month-old and 6-month-old mice, respectively, and p = .04 and .05 for P-AMPK/AMPK ratio
at 3-month-old and 6-month-old mice, respectively)
(Figure 7A,B,G–I). There is no significant difference in
AMPK and P-AMPK protein levels in 3-month-old AF
mouse cardiac tissue compared with their age-matched
db/db mouse, whereas P-AMPK/AMPK ratio was significantly decreased in 3-
month-
old AF mice heart
tissue compared with their age-matched db/db mouse
(p = .04) (Figure 7A,B,G–I). However, P-AMPK protein
levels as well as the P-AMPK/AMPK ratio, were significantly decreased in 6-month-old AF mouse cardiac
tissue compared with their age-matched db/db mouse
(p = .04 and <.0001 for P-AMPK and P-AMPK/AMPK
ratio, respectively) (Figure 7A,B,G–I). Additionally,
AF mouse cardiac tissue showed a significant reduction in P-AMPK protein levels as well as the P-AMPK/
AMPK ratio at 6 months compared with their state at
3 months (p = .02 and .03 for P-AMPK and P-AMPK/
AMPK ratio, respectively) (Figure 7A,B,G–I). Both AKT
and P-AKT protein levels as well as P-AKT/AKT ratio

were significantly reduced in 3-month-old db/db mouse
cardiac tissue compared with their age-matched db/m
control (p = .04, .008 and .04 for AKT, P-AKT, and P-
AKT/AKT ratio, respectively) (Figure 7A,B,J–L). There
is no significant difference in AKT protein levels in
6-month-old db/db mouse cardiac tissue compared with
their age-matched db/m control, whereas P-AKT protein levels as well as the P-AKT/AKT ratio were significantly decreased in 6-month-old db/db mouse cardiac
tissue compared with their age-matched db/m control
(p = .0001 and .0007 for P-AKT and P-AKT/AKT ratio,
respectively) (Figure 7A,B,J–L). P-AKT protein levels
as well as the P-AKT/AKT ratio were significantly decreased in the cardiac tissue of both 3-month-old and
6-month-old AF compared with their age-matched db/
db mice (p = .02 and .03 for P-AKT in 3 months and
6 months, respectively, p = .04 and .0009 for P-AKT/AKT
ratio in 3 months and 6 months, respectively). However,
cardiac AKT protein levels were decreased only in
3-month-old AF mice compared with age-matched db/
db mice (p = .05) (Figure 7A,B,J–L). Additionally, AF
mouse heart showed a significant reduction in P-AKT/
AKT ratio at 6-month-old compared with 3-month-old
(p = .001) (Figure 7A,B,J–L).

3.9 | APN exerts its proangiogenic effect
by activating AMPK/AKT cascade in
mouse coronary endothelial cells
To affirm the proangiogenic effects of AMPK in APN-
induced coronary angiogenesis, we pretreated MCECs,
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F I G U R E 7 Impaired levels of APN and its downstream signaling molecules, including AdipoR1, AdipoR2, APPL1, AMPK, P-AMPK,
AKT, and P-AKT in ALDH2 mutant diabetic mice hear. (A) Representative Western blot (WB) band images of APN, AdipoR1, AdipoR2,
APPL1, AMPK, P-AMPK, AKT, P-AKT, and GAPDH proteins using whole cardiac tissue lysates from 3-month-old db/m (WT), db/db
(diabetic), AL (ALDH2 mutant) and AF (ALDH2 mutant with diabetes) mice. (B) Representative WB band images of APN, AdipoR1,
AdipoR2, APPL1, AMPK, P-AMPK, AKT, P-AKT, and GAPDH proteins using whole cardiac tissue lysates from 6-month-old db/m, db/
db, AL, and AF mice. (C) Quantification of WB data of APN protein levels stated in panels A and B. N = 6 for each group, each bar
represents the mean ± SEM. (D) Quantification of WB data of AdipoR1 protein levels stated in panels A and B. N = 6 for each group, each
bar represents the mean ± SEM. (E) Quantification of WB data of AdipoR2 protein levels stated in panels A and B. N = 6 for each group,
each bar represents the mean ± SEM. (F) Quantification of WB data of APPL1 protein levels stated in panels A and B. N = 6 for each group,
each bar represents the mean ± SEM. (G) Quantification of WB data of AMPK protein levels stated in panels A and B. N = 6 for each group,
each bar represents the mean ± SEM. (H) Quantification of P-AMPK levels and each bar represents the mean ± SEM. (I) Quantification of
P-AMPK/AMPK ratio stated in panels H and G, respectively, each bar represents the mean ± SEM. (J) Quantification of WB data of AKT
protein levels stated in panels A and B. N = 6 for each group, each bar represents the mean ± SEM. (K) Quantification of WB data of P-AKT
protein levels stated in panels A and B. N = 6 for each group, each bar represents the mean ± SEM. (L) Quantification of P-AKT/AKT ratio
stated in panels J and I, respectively. Each bar represents the mean ± SEM. APN, adiponectin; ns, not significant.

spheroids, and aortic rings with 10 μM compound C (CC),
an AMPK inhibitor, along with 10 ng/μl APN (as mentioned in Figure 1D) and subsequently performed tube
formation, spheroid and aortic ring assays, and extracted
proteins from MCECs for WB analysis.
APN-treated MCECs significantly increased tube formation on Matrigel compared with the control (p = .009)
(Figure 8A,C,P). However, CC-
treated MCECs significantly decreased tube formation (p < .0001 vs. both control
and APN) (Figure 8A,C,D,P). CC pretreatment followed
by APN treatment completely abrogated APN-
induced

increase in tube formation in MCECs (p < .0001 vs. both
control and APN) (Figure 8A,C–E,P). However, there
is no significant difference in tube formation between
CC-treated and CC pretreatment following APN-treated
MCECs (Figure 8D,E,P). Similarly, APN-treated spheroids
significantly increased sprout growth on the collagen matrix compared with the control (p = .04) (Figure 8F,H,Q).
However, CC-
treated spheroids significantly decreased
sprout growth (p < .0001 vs. both control and APN)
(Figure 8F,H,I,Q). CC pretreatment followed by APN
treatment completely abrogated APN-induced increase in
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F I G U R E 8 Role of AMPK inhibition in APN-induced coronary angiogenesis. (A–E) Representative micrographs of tube formation
on Matrigel by control, DMSO, 10 ng/μl adiponectin, 10 μM compound C and 1 h compound C pretreatment following 2 h of adiponectin
treated MCECs. (F–J) Representative micrographs of sprout formation on collagen matrix by control, DMSO, 10 ng/μl adiponectin, 10 μM
compound C and 1 h compound C pretreatment following 2 h of adiponectin treated spheroids. (K–O) Representative micrographs of sprout
formation on collagen matrix by control, DMSO, 10 ng/μl adiponectin, 10 μM compound C and 1 h compound C pretreatment following 2 h
of adiponectin treated aortic rings isolated from 6 months old db/m control mouse. (P) Quantitative data of circle counts/HPF with different
treatments stated in A through E. N = 6 for each group. Each bar represents the mean ± SEM. (Q) Quantitative data of node counts/
spheroid with different treatments stated in F through J. N = 7 for each group. Each bar represents the mean ± SEM. (R) Quantitative data
of sprouting area/HPF with different treatments stated in K through O. N = 6 for each group. Each bar represents the mean ± SEM. (S)
Representative Western blot (WB) band images of AMPK, P-AMPK, AKT, P-AKT, and GAPDH proteins in DMSO, 10 ng/μl adiponectin,
10 μM compound C, and 1 h compound C pretreatment following 2 h of adiponectin treated MCECs. (T) Quantification of WB data of AMPK
protein levels stated in panel S. N = 6 for each group, each bar represents the mean ± SEM. (U) Quantification of WB data of P-AMPK
protein levels stated in panel S. N = 6 for each group, each bar represents the mean ± SEM. (V) Quantification of P-AMPK/AMPK protein
ratio stated in panels T and U. Each bar represents the mean ± SEM. (W) Quantification of WB data of AKT protein levels stated in panel S.
N = 6 for each group, each bar represents the mean ± SEM. (X) Quantification of WB data of P-AKT protein levels stated in panel S. N = 6
for each group, each bar represents the mean ± SEM. (Y) Quantification of P-AKT/AKT protein ratio stated in panels W and X. Each bar
represents the mean ± SEM. APN, adiponectin; CC, compound C; DMSO, dimethyl sulfoxide; HPF, high power field; ns, not significant.
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sprout growth from spheroids (p < .0001 vs. both control
and APN) (Figure 8F,H,I,J,Q). However, there is no significant difference in sprout growth between CC-treated
and CC pretreatment following APN-treated spheroids
(Figure 8I,J,Q). Likewise, APN-treated mouse aortic rings
significantly increased sprout growth on collagen matrix
compared with the control (p = .0001) (Figure 8K,M,R).
However, CC-treated aortic rings significantly decreased
sprout growth (p = .0004 vs. control and p < .0001 vs. APN)
(Figure 8K,M,N,R). CC pretreatment followed by APN
treatment completely abrogated APN-induced increase in
sprout growth from aortic rings (p = .0005 vs. control and
p < .0001 vs. APN) (Figure 8K,M–O,R). However, there is
no significant difference in sprout growth between CC-
treated and CC pretreatment following APN-treated aortic
rings (Figure 8N,O,R). Our WB data showed that there is
no significant difference in AMPK protein levels in APN-
treated MCECs compared with the control MCECs. CC-
treated MCECs as well as CC pretreated MCECs followed
by APN treatment did not show any significant difference in AMPK protein levels compared with the control
MCECs (Figure 8S,T). However, P-AMPK levels as well as
the P-AMPK/AMPK ratio were significantly increased in
APN-treated MCECs compared with the controls (p = .04
and .05 for P-AMPK and P-AMPK/AMPK ratio, respectively) (Figure 8S,U,V). CC-treated MCECs significantly
decreased P-AMPK protein levels as well as the P-AMPK/
AMPK ratio compared with the control (p = .04 for both
P-
AMPK and P-
AMPK/AMPK ratio) (Figure 8S,U,V).
Similarly, CC pretreated MCECs followed by APN treatment significantly decreased P-AMPK protein levels as
well as the P-AMPK/AMPK ratio compared with the control (p = .05 for both P-AMPK and P-AMPK/AMPK ratio)
(Figure 8S,U,V). However, there is no significant difference in P-AMPK protein levels as well as the P-AMPK/
AMPK ratio between CC-treated and CC pretreatment following APN-treated MCECs (Figure 8S,U,V).
There is no significant difference in AKT protein levels in APN-treated MCECs compared with the control.
Likewise, CC-treated MCECs as well as CC pretreated
MCECs followed by APN treatment did not show any
significant difference in AKT protein levels compared
with the control (Figure 8S,W). However, P-AKT protein levels as well as the P-AKT/AKT ratio significantly
increased in APN-
treated MCECs compared with the
controls (p = .05 for both P-AKT and P-AKT/AKT ratio,
respectively) (Figure 8S,X,Y). CC-
treated MCECs significantly decreased P-AKT protein levels as well as the
P-
AKT/AKT ratio compared with the control (p = .05
and .03 for P-AKT and P-AKT/AKT ratio, respectively)
(Figure 8S,X,Y). Similarly, CC pretreated MCECs followed
by APN treatment significantly decreased P-AKT protein
levels as well as the P-AKT/AKT ratio compared with the
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control (p = .0009 and .01 for P-AKT and P-AKT/AKT
ratio) (Figure 8S,U,V). However, there is no significant difference in P-AKT protein levels as well as the P-AKT/AKT
ratio between CC-treated and CC pretreatment following
APN-treated MCECs (Figure 8S,X,Y).
To affirm that AKT is an indispensable downstream
target of AMPK in APN-induced coronary angiogenesis,
we pretreated spheroids and aortic rings with 10 μM API-
1, a specific AKT inhibitor, along with 10 ng/μl APN (as
mentioned in Figure 1D) and subsequently performed
spheroid and aortic ring assays and extracted proteins
from MCECs for WB analysis.
APN-treated spheroids significantly increased sprout
growth on the collagen matrix compared with the
control (p = .001) (Figure 9A,C,K). However, API-
1-
treated spheroids significantly decreased sprout growth
(p < .0001 vs. both control and APN) compared with the
control (Figure 9A,C,D,K). API-1 pretreatment followed
by APN treatment completely abrogated APN-
induced
increase in sprout growth from spheroids (p < .0001 vs.
APN) (Figure 9A,C,E,K). However, there is no significant difference in sprout growth between API-1-treated
and API-1 pretreatment following APN-treated spheroids
(Figure 9D,E,K). Likewise, APN-
treated 6 months old
mouse aortic rings significantly increased sprout growth
on collagen matrix compared with the control (p < .0001)
(Figure 9F,H,L). However, API-
1-
treated aortic rings
significantly decreased sprout growth (p = .02 vs. control and p < .0001 vs. APN) compared with the control
(Figure 9F,H,I,L). API-1 pretreatment followed by APN
treatment completely abrogated APN-
induced increase
in sprout growth from the aortic rings (p = .04 vs. control and p < .0001 vs. APN) (Figure 9F,H,J,L). However,
there is no significant difference in sprout growth between
API-
1-
treated and API-
1 pretreatment following APN-
treated aortic rings (Figure 9I,J,L). Our WB data showed
that there is no significant difference in AMPK protein
levels in APN-treated MCECs compared with the control
(Figure 9M,N). API-1-treated MCECs as well as API-1 pretreated MCECs followed by APN treatment, did not show
any significant change in AMPK protein levels compared
with the control (Figure 9M,N). However, P-AMPK levels,
as well as the P-AMPK/AMPK ratio, were significantly increased in APN-treated MCECs compared with the controls (p = .04 for both P-
AMPK and P-
AMPK/AMPK)
(Figure 9M,O,P). API-1-treated MCECs did not decrease
the P-
AMPK/AMPK ratio compared with the control
(Figure 9M,P). Similarly, API-1 pretreated MCECs followed by APN treatment, did not decrease the P-AMPK/
AMPK ratio compared with the control (Figure 9M,P).
There is no significant difference in AKT protein levels in APN-treated MCECs compared with the control.
Likewise, API-1-treated MCECs as well as API-1 pretreated
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F I G U R E 9 Role of AKT inhibition in APN-induced coronary angiogenesis. (A–E) Representative micrographs of sprout formation
on collagen matrix by control, DMSO, 10 ng/μl adiponectin, 10 μM API-1, and 1 h API-1 pretreatment following 2 h of adiponectin treated
spheroids. (F–J) Representative micrographs of sprout formation on collagen matrix by control, DMSO, 10 ng/μl adiponectin, 10 μM API-1,
and 1 h compound C pretreatment following 2 h of adiponectin treated aortic rings isolated from 6 months old db/m control mouse. (K)
Quantitative data of node counts/spheroid with different treatments stated in F through J. N = 9–11 for each group. Each bar represents the
mean ± SEM. (L) Quantitative data of sprouting area/HPF with different treatments stated in K through O. N = 6–8 for each group. Each bar
represents the mean ± SEM. (M) Representative Western blot (WB) band images of AMPK, P-AMPK, AKT, P-AKT, and GAPDH proteins
in DMSO, 10 ng/μl adiponectin, 10 μM API-1, and 1 h API-1 pretreatment following 2 h of adiponectin treated MCECs. (N) Quantification
of WB data of AMPK protein levels stated in panel M. N = 6 for each group, each bar represents the mean ± SEM. (O) Quantification of WB
data of P-AMPK protein levels stated in panel M. N = 6 for each group, each bar represents the mean ± SEM. (P) Quantification of P-AMPK/
AMPK protein ratio stated in panels N and O. Each bar represents the mean ± SEM. (Q) Quantification of WB data of AKT protein levels
stated in panel M. N = 6 for each group, each bar represents the mean ± SEM. (R) Quantification of WB data of P-AKT protein levels stated
in panel M. N = 6 for each group, each bar represents the mean ± SEM. (S) Quantification of P-AKT/AKT protein ratio stated in panels Q
and R. Each bar represents the mean ± SEM. APN, adiponectin; DMSO, dimethyl sulfoxide; HPF, high power field; ns, not significant.

MCECs followed by APN treatment, did not show any significant difference in AKT protein levels compared with
the control (Figure 9M,P). However, P-AKT levels, as well
as the P-AKT/AKT ratio significantly increased in APN-
treated MCECs compared with the controls (p = .02 and .04
for P-AKT and P-AKT/AKT, respectively) (Figure 9M,R,S).
API-1-treated MCECs significantly decreased P-AKT protein levels, as well as the P-AKT/AKT ratio compared with
the control (p = .003 and .01 for P-AKT and P-AKT/AKT

ratio, respectively) (Figure 9M,R,S). Similarly, API-1 pretreated MCECs followed by APN treatment, significantly
decreased P-AKT protein levels, as well as the P-AKT/
AKT ratio compared with the control (p = .02 and .03 for
P-AKT and P-AKT/AKT ratio) (Figure 9M,R,S). However,
there is no significant difference in P-AKT protein levels,
as well as the P-AKT/AKT ratio between API-1-treated
and API-1 pretreatment following APN-treated MCECs
(Figure 9M,R,S).
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3.10 | Pharmacological activation
of ALDH2 improves APN sensitivity to
coronary angiogenesis in 6-month-old db/
db, AL, and AF mice
To confirm the role of exogenous activation of ALDH2
in APN-induced coronary angiogenesis in 6-month-old
db/db, AL and AF mice, we treated the aortic rings and
cardiac tissue fragments from those mice with alda1 according to the protocol mentioned elsewhere in the manuscript (Figures 1E and S2). The aortic ring assay that
demonstrates angiogenesis showed that APN treatment
significantly increased angiogenesis in db/m mice compared with their controls (p = .02). Alda1 pretreatment
followed by APN treatment potentiated APN-induced increased angiogenesis compared with their control as well
as the APN alone (p = .0001 vs. control and p = .05 vs.
APN alone) (Figure 10A–E,U). However, in db/db mouse,
there is no significant increase in angiogenesis due to
APN treatment, whereas Alda1 pretreatment followed by
APN treatment significantly increased angiogenesis compared with their controls and the APN alone (p = .0003 vs.
control and p = .0005 vs. APN alone) (Figure 10F–J,U).
Similarly, in AL mice, there is no significant increase
in angiogenesis due to APN treatment, whereas Alda1
pretreatment followed by APN treatment significantly

increased angiogenesis compared with the control and the
APN alone (p = .0003 vs. control and p = .0004 vs. APN
alone) (Figure 10K–O,U). Likewise, in AF mice, there is
no significant increase in angiogenesis due to APN treatment, whereas Alda1 pretreatment followed by APN
treatment significantly increased angiogenesis compared
with the control and the APN alone (p = .0009 vs. control
and p = .02 vs. APN alone) (Figure 10P–U).
The cardiac tissue sprouting assay demonstrating angiogenesis showed that Alda1-
treatment significantly
increased angiogenesis in db/m mice compared with controls (p = .0008) (Figure S2A,E,I). Similarly, Alda1 treatment significantly increased angiogenesis in the cardiac
tissue of db/db, Al, and AF mice compared with their controls (p = .01, .04, and .04 for db/db, AL, and AF, respectively) (Figure S2B–D,F–I).

4
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DISC USSION

This study showed that APN dose-dependently increased
coronary angiogenesis, which was evident from three different assays, including circle counts in the tube formation assay, node counts in the spheroid assay, and relative
sprouting area in the aortic ring assay (Figure 2). 4HNE
reduced APN-induced coronary angiogenesis significantly

F I G U R E 1 0 Role of an exogenous increase in ALDH2 activity in APN-induced coronary angiogenesis in db/db, AL, and AF mice. (A–E)
Representative micrographs of sprout formation by 6-month-old db/m mouse aortic rings on collagen matrix after 24 h of alda1 pretreatment
followed by 72 h of adiponectin treatment. Magnification: 10×. (F–J) Representative micrographs of sprout formation by 6-month-old db/db
mouse aortic rings on collagen matrix after 24 h of alda1 pretreatment followed by 72 h of adiponectin treatment. Magnification: 10×. (K–O)
Representative micrographs of sprout formation by 6-month-old AL mouse aortic rings on collagen matrix after 24 h of alda1 pretreatment
followed by 72 h of adiponectin treatment. Magnification: 10×. (P–T) Representative micrographs of sprout formation by 6-month-old AF
mouse aortic rings on collagen matrix after 24 h of alda1 pretreatment followed by 72 h of adiponectin treatment. Magnification: 10×. (U)
Quantitative data of sprouting area/aortic ring stated in A through T. N = 6 for each group. Each bar represents the mean ± SEM. APN,
adiponectin.
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along with APN signaling cascade molecules. These
4HNE-induced changes were augmented by ALDH2 inhibition and reduced by ALDH2 activation. Db/db mice exhibit HFpEF at 6 months of age compared with 3 months
of age and this HFpEF was aggravated in 6-month-old
AF mice, which were created by crossbreeding ALDH2*2
mutant mice with db/db mice. We also found that AF
mice exhibit decreased coronary angiogenesis along with
decreased APN signaling but with increased serum adiponectin levels at 6-months of age. This phenomenon can
be defined as APN resistance, as we found that APN treatment did not increase angiogenesis in them. Finally, when
we treated the tissue from these APN-resistant mice with
Alda-1, we found increases in APN-induced angiogenesis.
Thus, ALDH2 activity is critical in APN signaling and sensitizing in coronary angiogenesis with HFpEF associated
with diabetes. Although exact molecular mechanisms
can be our future direction, it must be due to attenuating
4HNE-mediated deleterious effects.
A study by Piao et al. showed that treatment with
500 μM H2O2, an important ROS, significantly reduced
AdipoR1 protein levels in young-
aged HUVECs compared with the control. The same study also showed that
siRNA-mediated knockdown of AdipoR1 has been proven
to reduce migration/invasion, proliferation, and subsequent reduction of angiogenesis in HUVECs.29 Likewise,
AdipoR2 has shown to play an important role as a proangiogenic factor in APN-induced revascularization in a
mouse model of chronic hind limb ischemia.30 A study by
Cheng et al. demonstrated that simultaneous inhibition
of AdipoR1 and AdipoR2 activity using duplex stealth
RNA interference (RNAi) abrogated the phosphorylation
of eNOS in HUVECs. This study also showed that siRNA-
mediated inhibition of APPL1 completely abrogated APN-
induced phosphorylation of AMPK and eNOS, as well as
complex formation between eNOS and heat shock protein 90, and subsequent reduction of NO generation in
HUVECs. They further showed that both APPL1 expression and APN-induced vasodilation were significantly decreased in db/db mouse compared with their age-matched
lean littermates.25 A study by Cao et al. demonstrated that
globular APN exerts its cardioprotective role on angiotensin II-induced atrial hypertrophy and fibrosis in neonatal Sprague–Dawley rats through the activation of the
AdipoR1/APPL1 signaling pathway.31 APPL1 overexpressing transgenic mice is protected from high-fat-diet (HFD)-
induced development of cardiac dysfunction, including
decreased EF, decreased FS and increased end-diastolic
volume relative to their age-matched WT control fed with
HFD.32 APN has been shown to increase cell differentiation, migration, as well as angiogenesis of HUVECs and
rabbit corneal ECs through the phosphorylation of AKT
and AMPK.33 A study by Chen et al. showed that treatment
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with IMD1-53, a novel member of the calcitonin gene–
related peptide family, increased the proliferation, migration, and tube formation by myocardial microvascular
endothelial cells.34 This study further showed that chronic
administration of IMD1-53 in post-MI rats significantly
increased myocardial AMPK levels, increased capillary
density in the peri-infarct zone, attenuated ventricular remodeling, and improved cardiac performance. However,
co-administration of compound C, an AMPK inhibitor,
significantly attenuated the IMD1-
53-
induced effect in
post-MI rat myocardium. Findings from this study suggest
that activation of AMPK is an important step in myocardial angiogenesis.35 Findings from all studies above suggest that APN exerts its proangiogenic function in vascular
EC through the activation of AdipoR1/AdipoR2-APPL1-
AMPK-AKT signaling pathway. Therefore, in this study,
we tried to determine the role of 4HNE and/or ALDH2 in
APN signaling that results in increased coronary angiogenesis in cultured MCECs as well as mouse tissue samples.
WB data in Figure 4 showed that 4HNE treatment significantly decreased AdipoR1, APPL1, P-AMPK, and P-AKT
protein levels in cultured MCECs (Figure 4). Inhibition
of ALDH2 activity with DSF exacerbated 4HNE-induced
decrease in AdipoR1, APPL1, P-AMPK, and P-AKT protein levels in cultured MCECs, whereas the potentiation
of ALDH2 activity with alda1 rescued the 4HNE-induced
decrease in AdipoR1, APPL1, P-AMPK and P-AKT protein
levels in cultured MCECs (Figure 4).
To translate our cell culture study in vivo, we used db/
db mouse as a T2DM model and its control db/m mouse
as well as AL mouse as a model of low intrinsic ALDH2
activity and AF mouse as a model of T2DM with low intrinsic ALDH2 activity. Recently, we showed that there
is a reduction in ALDH2 activity and an elevation in
4HNE adduct levels in our db/db mouse cardiac tissue.7
Additionally, db/db and AF mice started to show HFpEF
around 6-months of age which was absent at 3 months
of age when diabetes alone was present without HFpEF
manifestation (Tables 1 and 2). Thus, we checked if decreases in both angiogenesis and APN signaling would
manifest at 3 months or 6 months.
An in vivo study demonstrated that APN antisense
transgenic mice that were attenuated to caloric restriction (CR)-induced improved cardiac dysfunction as well
as AMPK phosphorylation compared with their age-
matched WT control. However, administration of recombinant APN restored CR-induced improved cardiac
function and inhibition of AMPK phosphorylation.38
Globular APN treatment has been shown to elevate NO
production in bovine aortic endothelial cells through the
activation of the PI3-AKT signaling pathway.39 Although
systemic APN level is an indicator of CVD pathophysiology, APN resistance or decrease in APN signaling confers
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the response of APN to target organs, including adipocytes, skeletal muscle, the liver, vascular tissue, and the
heart. A study in rodents showed that serum APN levels
increased significantly in adult male Sprague–
Dawley
rats after 8 weeks of HFD, and the levels rapidly declined
thereafter. However, vascular tissue levels of P-AMPK and
P-eNOS were significantly decreased in all observed time
points. Additionally, expression of AdipoR1 and AdipoR2
were significantly reduced in the aortic tissue of 16 weeks
old rats.40 Findings from their study suggest that HFD-
induced obesity/T2DM contributes to the development of
APN-resistance by decreasing the expression of AdipoR1/
AdipoR2 as well as the levels of P-AMPK and P-eNOS in
aortic tissue. However, there is no published study that
showed the role of ALDH2 in APN signaling in CECs and
subsequent increased coronary angiogenesis in diabetic
heart. We are the first to reveal the role of ALDH2 activity
in APN signaling in CECs and subsequent increased coronary angiogenesis in the diabetic heart. Our current study
showed that reduced ALDH2 activity in 6-month-old db/
db mice and 3-month-old and 6-month-old AL and AF
mice is associated with diminished APN response to coronary angiogenesis, as indicated in Figure 5. This study
further demonstrated that a pharmacological increase in
ALDH2 activity with alda1 rescued the APN response to
coronary angiogenesis in 6-month-old db/db, AL and AF
mice as indicated in Figure 9. Alda-1 can augment ALDH2
activity in WT and mutant ALDH2.36,41 Therefore, we can
speculate that activation of ALDH2 plays a critical role in
APN response to increased coronary angiogenesis in the
diabetic heart.
Elevated levels of plasma APN were observed in different CVDs outcomes. For instance, a study in which 107
outpatients with coronary artery disease (CAD) demonstrated that plasma APN levels were significantly elevated in CAD with overt HF (group 3) compared with
CAD without left ventricular systolic dysfunction (group
1) and CAD with left ventricular dysfunction without HF
symptoms (group 2).40 A cohort study with 54 CHF patients with left ventricular systolic dysfunction showed
elevated plasma APN levels compared with age and
gender-matched healthy controls.41 Another study in 195
CHF patients demonstrated that plasma APN levels are
positively associated with mortality as well as plasma levels of NT-proBNP, an important biomarker of HF.42 The
current study showed that serum APN levels in AF mice
were significantly elevated in 6 months, as indicated in
Figure 6B. However, the downstream signaling protein of
APN, including AdipoR1, AdipoR2, APPL1, P-AMPK, and
P-AKT were significantly reduced in both 3-month-old
and 6-month-old db/db and AF mouse cardiac tissues.
Additionally, the levels of cardiac AdipoR2 were significantly decreased in both 3-month-old and 6-month-old

ROY et al.

AL mice. Therefore, we can speculate that intrinsic elevation of 4HNE levels with low ALDH2 activity is associated
with elevated serum APN levels as well as downregulation of AdipoR1, AdipoR2, APPL1, P-AMPK, and P-AKT
in the cardiac tissue of diabetic mouse, which results in
decreased coronary angiogenesis. Additionally, decreased
APN response to coronary angiogenesis in AL mice results
from the downregulation of AdipoR2 levels in cardiac tissue. All these indicate that 4HNE and low ALDH2 activity
contributes to APN resistance and as well as a decrease in
coronary angiogenesis in HFpEF associated with diabetes.
According to Shimano et al., APN-KO mice showed
increased cardiac hypertrophy, pulmonary congestion,
left ventricular fibrosis, LV systolic dysfunction, and
reduced myocardial capillary density due to reduced
AMPK phosphorylation and subsequent downregulation
of VEGF after transverse aortic constriction surgery relative to WT mice.43 Another study by Ouchi et al. showed
APN-induced HUVECs differentiation and subsequent
angiogenesis through the phosphorylation of AMPK
and AKT.33 They also demonstrated that inhibition of
AMPK with dominant-negative AMPKα2 decreased the
phosphorylation of AKT and subsequent reduction of
APN-induced differentiation, migration, and angiogenesis of HUVECs.33 This study suggests that APN exerts
its proangiogenic role in HUVECs through the activation
of AMPK/AKT signaling, and AMPK is an upstream target of Akt. Our current studies using MCECs and ex-vivo
mouse aortic rings demonstrated that pharmacological
inhibition of AMPK with compound C significantly decreased the phosphorylation of the AMPK/AKT cascade,
which results in complete abrogation of APN-induced
increased angiogenesis (Figure 8). Similar to ours, most
studies implicate AMPK as the main downstream signaling in coronary angiogenesis induced by APN. When we
checked if there are other pathways for APN, there is an
in vitro study showed that APN exerts its proangiogenic
role in human endothelial progenitor cells through the
activation of the MEK/ERK signaling pathway and subsequent increase in VEGF expression in rheumatoid arthritis (PMID: 34685605).
We further showed that pharmacological inhibition of
AKT with API-1 significantly decreased the phosphorylation of AKT in MCECs, along with the reduction in coronary angiogenesis as indicated by the spheroid and aortic
ring assays, whereas there is no reduction in AMPK phosphorylation (Figure 9). Therefore, our study confers that
AMPK and AKT are required in APN-mediated increase
in coronary angiogenesis, and AMPK is an upstream target of AKT.
We can summarize our overall findings from this study
as 4HNE decreases coronary microvascular angiogenesis
in diabetic mouse hearts, and more specifically, in CECs
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F I G U R E 1 1 Cardioprotective role of
ALDH2 in 4HNE-induced downregulation
of APN signaling and subsequent decrease
in coronary angiogenesis in the diabetic
heart.

through the downregulation of adipoR1, APPL1, AMPK,
and AKT signaling pathway and possibly, the subsequent
culmination of APN-
resistance (Figure 11). Reduced
ALDH2 activity exacerbates 4HNE-induced downregulation of the adipoR1-APPL1-AMPK-AKT signaling pathway and subsequent APN resistance in diabetic mouse
hearts and, more specifically, in CECs, whereas increasing ALDH2 activity rescues the 4HNE-mediated effects
(Figure 11). Improving APN sensitization seems to be a
helpful strategy to reduce diabetes-mediated HFpEF, like
end-organ dysfunction.
Thus, in conclusion, we suggest that use of an effective
ALDH2 activator can be a viable therapeutic approach to
improve APN sensitivity to CECs and thereby coronary
angiogenesis in HFpEF associated with diabetes.
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